R Agarwal1, M Linch, S B Kaye. 1. Section of Medicine, Institute for Cancer Research, Sutton, Surrey SM2 5NG, UK.
Abstract
AIMS: Epithelial ovarian cancer is responsible for 4% of all cancer deaths in women, and the five-year overall survival of patients with advanced disease is 30-40%. Treatment currently comprises a combination of surgery and chemotherapy with carboplatin and paclitaxel. The main reason for treatment failure is that the majority of patients present with advanced disease, and current drugs are unable to effect a cure even in chemosensitive patients. This article systematically reviews novel therapeutic strategies that have been evaluated in patients with ovarian cancer in the last 5 years. METHODS: Pubmed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed) and American Society of Clinical Oncology Annual conference abstracts were searched using the terms "(phase I OR phase II OR phase III OR phase 1 OR phase 2 OR phase 3) AND (ovary OR ovarian) AND (cancer OR carcinoma)" from January 2000 to May 2005 to identify studies for potential inclusion in this review. Reviews of novel therapies in ovarian cancer were also used to identify additional clinical trials. FINDINGS: A wide range of therapeutic strategies are currently being evaluated in ovarian cancer. These include novel cytotoxics, small molecule inhibitors, monoclonal antibodies, gene therapy and immuno-therapy strategies. The rationale for the development of these agents includes enhancement of efficacy by targeting novel biological pathways, re-sensitisation to existing drugs, simplification of drug administration and/or reduction of drug-toxicity. CONCLUSIONS: Current developments have the potential to result in substantial improvements in the outlook for women with ovarian cancer.
AIMS: Epithelial ovarian cancer is responsible for 4% of all cancer deaths in women, and the five-year overall survival of patients with advanced disease is 30-40%. Treatment currently comprises a combination of surgery and chemotherapy with carboplatin and paclitaxel. The main reason for treatment failure is that the majority of patients present with advanced disease, and current drugs are unable to effect a cure even in chemosensitive patients. This article systematically reviews novel therapeutic strategies that have been evaluated in patients with ovarian cancer in the last 5 years. METHODS: Pubmed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed) and American Society of Clinical Oncology Annual conference abstracts were searched using the terms "(phase I OR phase II OR phase III OR phase 1 OR phase 2 OR phase 3) AND (ovary OR ovarian) AND (cancer OR carcinoma)" from January 2000 to May 2005 to identify studies for potential inclusion in this review. Reviews of novel therapies in ovarian cancer were also used to identify additional clinical trials. FINDINGS: A wide range of therapeutic strategies are currently being evaluated in ovarian cancer. These include novel cytotoxics, small molecule inhibitors, monoclonal antibodies, gene therapy and immuno-therapy strategies. The rationale for the development of these agents includes enhancement of efficacy by targeting novel biological pathways, re-sensitisation to existing drugs, simplification of drug administration and/or reduction of drug-toxicity. CONCLUSIONS: Current developments have the potential to result in substantial improvements in the outlook for women with ovarian cancer.
Authors: Kristopher J Kimball; Meredith A Preuss; Mack N Barnes; Minghui Wang; Gene P Siegal; Wen Wan; Huichien Kuo; Souheil Saddekni; Cecil R Stockard; William E Grizzle; Raymond D Harris; Rosemarie Aurigemma; David T Curiel; Ronald D Alvarez Journal: Clin Cancer Res Date: 2010-10-26 Impact factor: 12.531
Authors: Emily K Mader; Yoshihiro Maeyama; Yi Lin; Greg W Butler; Holly M Russell; Evanthia Galanis; Stephen J Russell; Allan B Dietz; Kah-Whye Peng Journal: Clin Cancer Res Date: 2009-11-24 Impact factor: 12.531
Authors: Analisa Difeo; Fei Huang; Jaya Sangodkar; Esteban A Terzo; Devin Leake; Goutham Narla; John A Martignetti Journal: Cancer Res Date: 2009-05-12 Impact factor: 12.701